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Anti-angiogenic effects of VEGF stimulation on
endothelium deﬁcient in phosphoinositide recycling
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Amber N. Stratman 1,2, Olivia M. Farrelly1,8, Constantinos M. Mikelis3,4,8, Mayumi F. Miller1,8,
Zhiyong Wang3,5,8, Van N. Pham1, Andrew E. Davis1, Margaret C. Burns1, Soﬁa A. Pezoa1, Daniel Castranova1,
Joseph J. Yano1, Tina M. Kilts6, George E. Davis7, J. Silvio Gutkind 3,5 & Brant M. Weinstein 1 ✉

Anti-angiogenic therapies have generated signiﬁcant interest for their potential to combat
tumor growth. However, tumor overproduction of pro-angiogenic ligands can overcome these
therapies, hampering success of this approach. To circumvent this problem, we target the
resynthesis of phosphoinositides consumed during intracellular transduction of proangiogenic signals in endothelial cells (EC), thus harnessing the tumor’s own production of
excess stimulatory ligands to deplete adjacent ECs of the capacity to respond to these
signals. Using zebraﬁsh and human endothelial cells in vitro, we show ECs deﬁcient in CDPdiacylglycerol synthase 2 are uniquely sensitive to increased vascular endothelial growth
factor (VEGF) stimulation due to a reduced capacity to re-synthesize phosphoinositides,
including phosphatidylinositol-(4,5)-bisphosphate (PIP2), resulting in VEGF-exacerbated
defects in angiogenesis and angiogenic signaling. Using murine tumor allograft models, we
show that systemic or EC speciﬁc suppression of phosphoinositide recycling results in
reduced tumor growth and tumor angiogenesis. Our results suggest inhibition of phosphoinositide recycling provides a useful anti-angiogenic approach.
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hosphoinositides are utilized as “second messengers” for a
wide variety of different intracellular signaling pathways, in
virtually every cell type. This includes receptor tyrosine
kinase pro-angiogenic signaling in endothelial cells (EC) through
receptors like vascular endothelial growth factor (VEGF) receptor
2 (VEGFR2), the VEGFA receptor, which uses phosphatidylinositol-(4,5)-bisphosphate (PIP2) as a key substrate for both phospholipase C-gamma 1 (PLCγ1) and phosphoinositide 3-kinase
(PI3K) mediated downstream signaling activation1–11. In order to
regenerate PIP2 consumed during signaling, diacylglycerol (DAG)
must be recycled to CDP-diacyglycerol (CDP-DAG) through the
activity of two vertebrate CDP-diacyglycerol synthase enzymes,
CDS1 and CDS21–8,12–17. CDP-diacylglycerol synthase (CDS)
activity is necessary to resynthesize phosphoinositide (PI), the
base molecule required for the generation of downstream PI
derivatives, such as PIP2. Loss or knockdown of either one of the
two CDS genes in ECs in vitro or in zebraﬁsh embryos in vivo
results in reduced angiogenesis, while excess PIP2 promotes
increased angiogenesis in wild type endothelium16. Importantly,
the vascular defects observed in cds2y54 null mutant zebraﬁsh
embryos that lack Cds2 but retain Cds1 activity seem to occur in
the absence of other obvious developmental abnormalities16,
suggesting that the endothelium is differentially more sensitive to
a reduced capacity to resynthesize phosphoinositides than other
cell types and tissues.
Anti-angiogenic therapies have been of signiﬁcant interest for a
number of years due to their potential to combat tumor growth
through cutting the tumor off from the host blood supply18–24.
However, the ability of tumors to overproduce pro-angiogenic
ligands and overcome targeted therapies has hampered this
approach to date25,26. An alternative way to circumvent this
problem is to target the re-synthesis of critical signaling substrates, like phosphoinositides, that are consumed during intracellular transduction of pro-angiogenic signals in ECs, thereby
harnessing the tumor’s own production of excess stimulatory
ligands to deplete adjacent host ECs of the capacity to respond to
these signals1,13,14,16,27–29.
Here we show using zebraﬁsh, human cells, and mice that ECs
deﬁcient in phosphoinositide recycling are uniquely sensitive to
increased stimulation by VEGFA and other angiogenic cytokines.
Instead of promoting increased angiogenesis, VEGFA stimulation
of PI recycling-deﬁcient endothelium suppresses angiogenesis
and decreases pro-angiogenic signaling, suggesting highly stimulated, actively angiogenic ECs might be differentially sensitive
to reduced PI recycling capacity compared to quiescent ECs. To
examine whether the sensitivity of angiogenically active endothelium to reduced PI recycling capacity could be harnessed as an
anti-angiogenic anti-tumor approach, we suppressed PI recycling
in mice and examined the effects on growth of allografted tumors.
Our results show that either systemic or EC speciﬁc suppression
of PI recycling results in reduced tumor growth, reduced proangiogenic signaling in the endothelium, and reduced tumor
angiogenesis. Together, these ﬁndings suggest that inhibition of
phosphoinositide recycling may provide a useful anti-angiogenic
approach, and highlights the general potential of targeting resynthesis of rate limiting signaling substrates as a therapeutic
strategy.
Results
Inhibiting phosphoinositide recycling sensitizes ECs to proangiogenic stimuli. Previously, we reported the discovery of
a zebraﬁsh mutant in the CDP-diacylglycerol synthase (cds2)
gene with defects in angiogenesis16. CDS activity is required for
resynthesis of phosphoinositides (PI), including phosphatidylinositol-(4,5)-bisphosphate, or PIP213,14,16,30 (Fig. 1a). In ECs,
2

PIP2 serves as a key substrate for both phospholipase C-gamma 1
(PLCγ1) and phosphoinositide 3-kinase (PI3K) dependent signaling downstream from multiple pro-angiogenic tyrosine kinase
receptors, such as VEGFR2, ﬁbroblast growth factor receptor 1
(FGFR1) and epidermal growth factor receptor (EGFR)1–8,31–34
(Fig. 1b). Loss or knockdown of either one of the two CDS genes
in ECs in vitro or in zebraﬁsh embryos in vivo results in reduced
angiogenesis (Fig. 1c, d, h–k, Supplementary Fig. 1)16.
From these studies, we predicted that exogenously supplying
PI substrates to the vasculature would rescue the aberrant EC
phenotypes in Cds2-deﬁcient zebraﬁsh, bypassing the need for
PI recycling. Indeed, delivery of a single “bolus” intravascular
injection of any PI species downstream of Cds2 dependent
recycling—PI, PI(4)P, PI(4,5)P2 or PIP3—reactivates EC activity
to largely reverse the angiogenic defects noted in 72 hpf cds2y54
mutant zebraﬁsh embryos (Supplementary Fig. 2A–M)16.
To further conﬁrm the role of PI recycling in angiogenesis, we
generated a zebraﬁsh mutant disrupting inositol monophosphatase
(impa2y602) (Supplementary Fig. 3A). The impa2 gene encodes a
critical enzyme in the phosphatidylinositol recycling pathway that
removes the ﬁnal phosphate group from myoinositol before it is
linked to CDP-DAG to regenerate PI (Fig. 1a, Supplementary
Fig. 3B), a step critical for the resynthesis of all subsequent PI
species. Like the cds2y54 mutants, zebraﬁsh maternal impa2y602
mutants also display defects in trunk angiogenesis at 32 hpf
(Supplementary Fig. 1C–F), demonstrating that interfering with
either of two different PI recycling enzymes (Cds or Impa) impairs
developmental angiogenesis. Importantly, the vascular defects
observed in cds2y54 and impa2y602 mutants appear in the absence
of other obvious developmental abnormalities (see ref. 24 for a
discussion of zebraﬁsh angiogenesis assays), suggesting that ECs are
more sensitive to partial reductions in phosphoinositide recycling
capacity compared to other cells and tissues. It is also worth noting
that for both cds2y54 and impa2y602 there are additional isoforms of
each of these enzymes that remain functional, i.e. Cds1 and Impa1,
generating animals that have compromised but not completely
absent PI recycling capacity.
To further explore the connections between phosphoinositide
recycling and pro-angiogenic signaling, we injected a CMV:
vegfaa transgene35 driving ubiquitous expression of Vegfaa into
the cds2y54 mutant zebraﬁsh. Instead of promoting increased
vessel growth, Vegfaa overexpression in cds2y54 null mutants or
cds2 morpholino (MO) treated embryos results in dramatically
reduced angiogenesis—including in the trunk intersegmental
vessels, central arteries in the brain, and sub-intestinal vascular
plexus (Fig. 1c–g, Supplementary Fig. 1). Longitudinal imaging
beginning at 24 hpf reveals that vessels fail to sprout and extend
properly (Supplementary Fig. 4). Sensitivity to Vegfaa is highly
speciﬁc to cds2y54 mutants, as other zebraﬁsh vascular mutants
including plcg1y10, ﬂk1y17, and etsrpy11 do not show reduced
angiogenesis when injected with CMV:vegfaa transgene (Supplementary Fig. 5).
Human ECs in vitro also exhibit this seemingly paradoxical
sensitivity to VEGFA stimulation when CDS2 activity is reduced.
Two independent siRNA targets were validated in human
umbilical vein endothelial cells (HUVECs), conﬁrming that both
suppressed CDS2 protein levels, disrupted HUVEC invasive
capacity in vitro, and suppressed p-ERK1/2 and p-AKT signaling
downstream of VEGFA stimulation (Supplementary Fig. 6A–C).
Further, CDS2 siRNA treatment reduces HUVEC proliferative
capacity but does not induce apoptosis (Supplementary Fig. 6D,
E). Exposing CDS2-deﬁcient HUVECs to increasing levels of
VEGFA stimulation results in decreased migratory capacity
in 3D endothelial invasion assays24 as compared to controls
(Fig. 1h–l), similar to the reduced angiogenesis noted upon
VEGFA stimulation in Cds2-deﬁcient zebraﬁsh.
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Role of cds2 in phosphoinositol recycling and VEGFR2 signal activation

b

P

VEGFA

Wild type

P
P
P P

IMPase
CDP-DAG

P

P

CDS1
PA

DAG
+IP3

PI(4,5)P2

PP
IP3
P

CDS2

PIP2

Control

PIP2 VEGFR2

PI(4)P

PIP3

PLCγ1

PI3K

ERK1/2

AKT

Arterial
specification,
angiogenesis

Cell
proliferation,
survival

CMV:vegfaa

PI

DAG

Myo-inositol
P Phosphate

c

cds2

d

y54

g

ISV sprouts stall

Dorsal aorta

e

f
ISV fail to
sprout

y54

mutants in vivo

n = 50 n = 50 n = 50 n = 50

100

mutant

% Intersegmental
vessel phenotype

a

Excess VEGF suppresses angiogenesis in cds2

80
To DLAV

60

To myoseptum
No sprouts

40
20
0

Wild cds2y54 Wild cds2y54
type
type
CMV:vegfaa
injected

Excess VEGFA suppresses angiogenesis in CDS2-Deficient HUVEC in vitro

i

Collagen
gel

VEGFA

18 h

siCDS2

siControl

j

37 °C

siControl

100

Average #
of invading cells

Media

l

k

HUVEC
transfected
with siRNA

Proportion of invading
siCDS2 to paired
control (%)

h

80
60
40
20

80
70
60
50
40
30
20
10
0
10 ng/ml 40 ng/ml 200 ng/ml
VEGFA concentration

0
200 ng/ml
10 ng/ml
40 ng/ml
VEGFA concentration

Plane of
imaging
siCDS2

m

Wild type

n

VEGF

cds2 y54 Mutant + High VEGF-A

VEGF

CDS1

VEGFR2

CDS1

PIP2

VEGF

CDS2

EC
activation

IP3+
DAG

Some EC
activation

p

Little/No
EC activation

q

DLAV

Excess VEGFA reduces PIP2 levels
in CDS2-deficient HUVEC
120

ISVs

rhVEGFA
(ng/ml)

100
80

CDS2
siRNA

0
40
200

60

DA

Control
siRNA

0
40
200

40
0

CD
CDS2
DS2
D
DS
S2

PIP2

IP3+
DAG

IP3 + DAG

CDS1

VEGFR2

CDS2
CD
DS2
D
DS
S2

PIP2

4
8
12
16
Hours post VEGFA addition

We further examined whether zebraﬁsh vessels and HUVECs
show increased sensitivity to VEGFA when inhibiting PI4K2A,
PI4K2B, and PIP5K1C—the kinases that directly phosphorylate PI
to generate PI(4,5)P2 (Supplementary Fig. 7)9–11. As with cds2y54
mutants, injecting exogenous CMV:vegfaa in zebraﬁsh treated
with PI4K inhibitor exacerbates the angiogenesis defects noted
(Supplementary Fig. 7A–G). VEGF-promoted anti-angiogenic
phenotypes are also recapitulated in HUVECs in which either
PI4K2B or PIP5K1C are suppressed using siRNA (Supplementary
Fig. 7H, I). Suppression of PI4K2B or PIP5K1C sensitizes HUVEC
to exogenously supplied VEGFA, with in vitro angiogenesis
reduced to a greater extent as VEGF concentration is increased
(Supplementary Fig. 7H, I). Suppression of PI4K2A did not cause
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signiﬁcant effects, nor did it cause additive effects when PI4K2A
and PI4K2B were inhibited together, suggesting PIPK2B is the
more critical of the two isoforms in this context.
Together, these data show that limiting PI availability via
suppression of CDS2 or downstream kinases in the PI recycling
pathway leads to anti-angiogenic effects that are exacerbated, not
ameliorated, by increased stimulation with VEGFA.
VEGFA stimulation results in reduced signaling in CDS2-deﬁcient
ECs. Defects in CDS2 reduces the capacity of ECs to regenerate
PIs for signal transduction (Fig. 1a, b, m, n)1,4–6,8,13,16,36,37.
We hypothesized that while initial and/or low-level VEGFA
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Fig. 1 CDS2 dependent angiogenic sprouting defects in vitro and in vivo are exacerbated by exogenous VEGFA addition. a Schematic diagram of
phosphoinositide recycling. CDS1, CDS2, and IMP enzymes facilitate regeneration of phosphoinositol after consumption of PIP2 (see Fig. S12 for details).
b VEGFR2 signaling schematic (modiﬁed from refs. 36,60). c–g Confocal images (c–f) and quantitation (g) of trunk intersegmental vessels (ISV) in 32hpf Tg
(ﬂi1a:egfp)y1 WT siblings (c, e) or cds2y54 mutants (d, f) injected with control (c, d) or CMV:vegfaa (e, f) DNA. Bars in g measure ISV that have not sprouted
(yellow), grown halfway up the trunk (blue), or formed a complete ISV (gray). Data is representative of three different experiments, n = 50 ISVs per
treatment group. h–j HUVEC 3D invasion assay used to model angiogenesis in vitro (h), with representative images from control and CDS2 siRNA-treated
cultures (i, j). k Quantiﬁcation of HUVEC cellular invasion into collagen gels at VEGFA doses indicated (n = 4 collagen gels; data is representative of three
independent experiments). l Quantiﬁcation of CDS2 siRNA HUVEC cellular invasion normalized to VEGFA dose-matched controls (see methods); Star
indicates signiﬁcance from control; plus indicates signiﬁcance from individual VEGFA doses (t-test). m–o Schematic model for phosphoinositide recycling,
CDS2, and angiogenesis. m Under normal conditions phosphoinositide recycling maintains PIP2 levels and VEGFA signal transduction. n Endothelium
defective for CDS2 has a reduced capacity to recycle phosphoinositides, but under conditions of initial or low-level VEGFA stimulation sufﬁcient PIP2 is
regenerated to maintain VEGFA signal transduction. o During sustained and/or high-level VEGFA stimulation, however, PIP2 levels cannot be maintained,
leading to a collapse of VEGFA signal transduction. p ELISA quantitation of PIP2 levels in control or CDS2 siRNA-treated HUVECs incubated with 0, 40, or
200 ng/ml VEGFA over a 16 h time course, normalized to levels in initial control siRNA-treated HUVEC without added VEGFA. Nine technical replicates
were measured per sample, per experiment. Data is graphed as the average of two experimental replicates. q Diagram illustrating procedure for
measurement of phospho-ERK1/2 in trunk endothelial nuclei by immunoﬂuorescence. r Quantitation of trunk endothelial phospho-ERK1/2 in 30 hpf cds2y54
mutants and WT siblings ± (with/without) CMV:vegfaa DNA (column 1 n = 5 biologically independent animals; column 2 n = 4 biologically independent
animals; column 3 n = 6 biologically independent animals; column 4 n = 7 biologically independent animals), data is representative of two independent
experiments. Star indicates signiﬁcance from control; plus indicates signiﬁcance from cds2y54 mutant—CMV:vegfaa DNA condition (t-test). Bars = 100 μm.
Box plots are graphed showing the median versus the ﬁrst and third quartiles of the data (the middle, top, and bottom lines of the box, respectively). The
whiskers demonstrate the spread of data within 1.5x above and below the interquartile range. All data points are shown as individual dots, with outliers
shown above or below the whiskers.

stimulation of CDS2-deﬁcient ECs might not substantially affect
PI recycling (Fig. 1m, n), higher levels and/or sustained VEGFA
stimulation would gradually deplete levels of PIP2 and other
phosphoinositides, halting signal transduction (Fig. 1o). To
examine this directly we measured endogenous PIP2 levels over
time in control and CDS2-deﬁcient HUVECs in vitro, challenged
with VEGFA (Fig. 1p). In control siRNA-treated HUVECs
VEGFA stimulation itself does not alter endogenous PIP2 levels
over a 16-hour time course (Fig. 1p). PIP2 levels are also not
signiﬁcantly reduced over 16 hours in CDS2 siRNA-treated
HUVECs in the absence of exogenously added VEGFA,
although the baseline level of PIP2 is slightly lower than in
controls. In contrast, however, exogenous VEGFA stimulation of
CDS2 siRNA-treated HUVECs results in a time-dependent
decrease in PIP2 levels, with more rapid reduction in PIP2
observed at higher VEGFA concentrations (Fig. 1p). Assessing
PI(4)P, PIP2 and PIP3 levels side-by-side at 12 hours after
VEGFA stimulation, in lipid fractions collected from the same
starting control versus CDS2-deﬁcient HUVEC populations,
reveals that all three PI species are depleted in a VEGFA dose
dependent manner in roughly the same proportions (Supplementary Fig. 2N–P). Together, these data show that reducing the
phosphoinositide recycling by suppressing CDS2 limits the
availability of all downstream PI species.
VEGF signaling downstream from VEGFR2 and PLCγ1 is
transduced via activation (phosphorylation) of ERK1/2 (Fig. 1b).
Injection of a CMV:vegfaa transgene into control zebraﬁsh
embryos results in a modest increase in phospho-ERK1/2 levels as
assessed by western blot analysis of excised zebraﬁsh trunk
tissue (Supplementary Fig. 8), or a more marked increase by
immunostaining analysis examining phospho-ERK1/2 speciﬁcally
in trunk ECs (Fig. 1q, r). Cds2-deﬁcient animals show somewhat
decreased phospho-ERK1/2, but injection of CMV:vegfaa transgene into Cds2-deﬁcient zebraﬁsh results in a more dramatic
decrease in phospho-ERK1/2, both by western blot (Supplementary Fig. 8) and by immunostaining analysis (Fig. 1r).
The seemingly paradoxical, negative effects of increased proangiogenic stimulation in Cds2-deﬁcient animals are not
restricted to Vegfaa. CDS2-deﬁcient HUVECs treated with FGF
or EGF show similar reductions in signaling activation (p-AKT
levels) to those seen with VEGFA treatment (Supplementary
4

Fig. 9A–C). Furthermore, overexpressing either phospholipase C
gamma (plcγ1) or a combination of phosphoinositol-3-kinase
(pi3k) isoforms (both consume PIP2 during pro-angiogenic
signaling; see Fig. 1b) in zebraﬁsh cds2y54 mutants leads to
increased inhibition of angiogenesis (Supplementary Fig. 9D–J),
suggesting that inhibiting PI recycling capacity is a generalizable
way to interfere with Plcγ- or Pi3k-dependent tyrosine kinase
mediated signaling pathways and is not solely restricted to
blocking Vegfaa signaling.
Inhibiting phosphoinositide recycling decreases tumor growth
and angiogenesis. Based on our ﬁndings, we hypothesized that
phosphoinositide recycling might provide an effective target for
anti-angiogenic anti-tumor treatment, as increased VEGFA and
other pro-angiogenic ligands secreted by tumors in response to
vascular insufﬁciency and hypoxia might facilitate anti-angiogenic
effects, rather than help to overcome them (Fig. 1o, see summary
schematic below). We used two different murine tumor allograft
models, Lewis Lung Carcinoma (LLC)38,39 and B16-F10 (B16)
melanoma39, to determine whether systemic or EC speciﬁc suppression of phosphoinositide recycling could speciﬁcally inhibit
tumor growth and tumor angiogenesis while maintaining the
normal, healthy vasculature throughout the rest of the animal. We
employed ﬁve different experimental paradigms to target phosphoinositide recycling in these tumor models: direct targeting of
Cds2 using separate translation or splice blocking vivoMorpholinos (vMO)40, inhibition of inositol monophosphatase (IMPase)
activity by the potent chemical inhibitor L-690,48841, inhibition of
IMPase activity by lithium chloride (LiCl) treatment, and inducible, endothelial-speciﬁc genetic deletion of Cds2 in mice via the
Cre/Lox system.
We administered murine Cds2 translation-blocking (vMO #1)
or splice-blocking (vMO #2) vMO40, versus a control vMO, into
mice allografted with LLC (Fig. 2a) or B16-F10 (Supplementary
Fig. 10A) tumors. The vMOs were introduced directly into the
circulation via tail vein or retro-orbital injection to increase
vascular delivery and ensure their bioavailability, beginning
two days prior to the implantation of tumor cells into each ﬂank
and continuing daily throughout the time course of tumor
growth (12–18 days). LLC (Fig. 2b, c) or B16-F10 (Supplementary
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Fig. 2 Anti-PIP2 recycling therapies suppress tumor growth. a Schematic of Lewis Lung Carcinoma (LLC) tumor allograft assay with representative tumor
images. Bar = 1 cm. b–g Cds2 vMO treatment (n = 10 biologically independent tumors for all groups). h–l L-690,488 small molecule inhibitor treatment
(control n = 8 biologically independent tumors, L-690,488 n = 19 biologically independent tumors). Quantitation of average tumor volume (b, h), ﬁnal
tumor weight (c, i) and ﬁnal tumor vascular density (d, j) at 12–15 days post-tumor implantation, in control versus Cds2 vMO or L-690,488-treated animals
(b–d versus h–j). d Quantitation of average tumor vascular density and representative images of CD31/PECAM labeled (green) versus DAPI (blue) LLC
tumor sections from control vMO (top) and Cds2 vMO (bottom) treated mice. White arrowheads indicate sites of CD31/PECAM positive blood vessel
labeling. Bar = 100 μm. For all vascular density measurement experiments: three images per tumor were acquired and vascular density measured for all
groups. A minimum of two slide sections from each tumor in b–g (taken from sections at least 10 slices apart) were analyzed. Representative of three
experimental replicates. e-g PIP2 “rescues” Cds2 vMO tumor inhibition. Quantitation of LLC average tumor volume (e), ﬁnal tumor weight (f), and tumor
vascular density (g) at 18 days post-tumor implantation in control vMO (n=8 biologically independent tumors), Cds2 vMO #2 (no liposomes, n = 9
biologically independent tumors), Cds2 vMO #2 + carrier liposome (no PIP2, n = 9 biologically independent tumors), or Cds2 vMO #2 + PIP2 loaded
liposome-treated (n = 8 biologically independent tumors), LLC-allografted mice. Data in (e-g) are normalized to the average starting size of each individual
tumor group at day 4, and shown as a percentage of the starting day 4 control (the PIP2 liposome injection start date). j Quantitation of average tumor
vascular density of LLC tumor sections from control and L-690,488-treated mice. For all vascular density measurement experiments: three images per
tumor were acquired and vascular density measured for all groups. A minimum of two slide sections from each tumor in h–l (taken from sections at least
10 slices apart) were analyzed. Representative of two experimental replicates. k, l Myo-inositol “rescues” L-690,488 tumor inhibition. Quantitation of LLC
average tumor volume (k) and ﬁnal tumor weight (l) at 15 days post-tumor implantation in control (untreated, n = 14 biologically independent tumors),
myo-inositol (n = 11 biologically independent tumors), L-690,488 (n = 12 biologically independent tumors), or L-690,488 + myo-inositol (n = 10
biologically independent tumors) treated LLC-allografted mice. Data in (k, l) are normalized to the control condition. For all panels: p ≤ 0.05, error bars ±
SEM. Star indicates signiﬁcance from control (t-test). Box plots are graphed showing the median versus the ﬁrst and third quartiles of the data (the middle,
top, and bottom lines of the box, respectively). The whiskers demonstrate the spread of data within 1.5x above and below the interquartile range. All data
points are shown as individual dots, with outliers shown above or below the whiskers.

Fig. 10B–D) allografted mice treated with either of the two Cds2
vMOs show decreased tumor volume and decreased ﬁnal tumor
weight compared to control vMO-injected mice. To determine if
Cds2 vMO treatments have direct effects on tumor cell
proliferation, we exposed isolated B16-F10 or LLC cells in vitro
to the estimated comparable doses of Cds2 vMO that they would
encounter in vivo and measured proliferation rates. In vitro
exposure of LLC or B16-F10 tumor cells to Cds2 vMO does not

alter proliferation rates, suggesting the reduced tumor growth
rates we note in our in vivo vMO studies are not the result of
inhibitory effects on the tumor cells themselves (Supplementary
Figs. 10E and 11A). Quantitation of tumor vessel density in CD31
immunostained sections revealed ~60–80% reduction in vessel
area in either LLC (Fig. 2D) or B16-F10 (Supplementary
Fig. 10F–I) tumor allografts from Cds2 vMO-treated animals
compared to controls. Treatment with the vMOs does not change
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the overall mass of the mice (Supplementary Fig. 11B), and liver
tissue from Cds2 vMO-treated mice showed no increase in
Caspase 3-positive apoptotic cells or decrease in vascularization
compared to livers from control vMO-treated animals (Supplementary Fig. 11C–E).
To further address the speciﬁcity of the Cds2 vMO treatments,
we carried out “rescue” experiments using daily intravascular
administration of BODIPY-PIP2 liposomes, supplied in conjunction with the retro-orbital vMO injections in LLC tumor allograft
assays (Fig. 2e–g; Supplementary Fig. 11F, G; following a similar
logic to that applied to the zebraﬁsh studies in Supplementary
Fig. 2). Although there are limitations associated with exogenously supplying PI substrates, including difﬁculties delivering
lipids to desired cell types and subcellular locations, metabolism
of the lipids once they enter cells, and differing fatty acid
acyl chain lengths on synthetic exogenous versus endogenous
phosphatidylinositides, the goal of these experiments is to bypass
the defect in PI recycling in CDS2-deﬁcient animals by directly
providing a downstream PI substrate. Daily co-injection of PIP2
liposomes into LLC-allografted mice treated with the Cds2 vMO
does reverse tumor growth and vascular density defects noted
with Cds2 vMO treatment alone (Fig. 2e–g; Supplementary
Fig. 11F, G). Retro-orbital intravascular injections were chosen
for these studies to make the liposomes more readily accessible to
the vascular endothelium compared to surrounding tissues.
Indeed, immunostaining of tumor slide sections for the BODIPY
ﬂuorophore (to amplify signal), conﬁrms enriched distribution of
the PIP2 liposomes in the vasculature versus the surrounding
tumor tissue (Supplementary Fig. 11H).
A similar experimental paradigm was carried out using the
potent inositolmonophosphatase (IMP) small molecule inhibitor L-690,48841 in mice with LLC-allografted tumors. IMP
catalyzes removal of the phosphate group from inositol-1phosphate to generate myo-inositol, which is then combined
with CDP-DAG (the product of the reaction catalyzed by CDS)
to regenerate phosphatidylinositol- PI (Fig. 1a). LLC tumors
from mice treated with L-690,488 show decreased tumor volume
and ﬁnal tumor weight compared to control DMSO-injected
mice (Fig. 2h, i). Examination of tumor vessel density by CD31
immunostaining of sections revealed ~50–60% reduction in
vessel area compared to controls (Fig. 2j). Treatment with
L-690,488 does not affect the overall mass of the mice nor does
it decrease normal vessel density in the liver (Supplementary
Fig. 12). We carried out “rescue” experiments by co-injecting
L-690,488 together with myo-inositol, the downstream product
of the reaction catalyzed by IMP16,30,41, in order to bypass the
reduced PI recycling capacity resulting from IMP inhibition
(Fig. 2k, l). Myo-inositol administration effectively reverses
tumor growth inhibition caused by L-690,488, suggesting the
effects of this drug on tumor growth are speciﬁc to inhibition of
IMP activity (Fig. 2k, l).
To further validate our L-690,488 results, we also targeted IMP
activity by treating with LiCl, a compound already used in
humans. Lithium is an effective inhibitor of IMP, although it also
has activity against other enzymes and pathways including WNT
signaling. We showed previously that LiCl inhibits angiogenesis
in developing zebraﬁsh in vivo and in EC invasion assays using
HUVEC in vitro, with the speciﬁcity of these effects for IMP
veriﬁed by myo-inositol rescue16. As with L-690,488, we ﬁnd that
treatment of mice with LiCl inhibits tumor growth and tumor
angiogenesis in both LLC and B16-F10 allografts, and that these
effects are largely reversed by co-administration of myo-inositol
(Supplementary Fig. 13). To determine if LiCl treatment has
direct effects on tumor cell proliferation, we exposed isolated
B16-F10 or LLC cells in vitro to the estimated comparable doses
of LiCl that they would encounter in vivo, and measured
6

proliferation rates (Supplementary Fig. 13E, I). Exposure of LLC
or B16-F10 tumor cells to LiCl does not alter proliferation rates at
10 and 20 uM doses, suggesting the reduced tumor growth rates
we note in our study following LiCl treatment are not a result of
inhibitory effects on the tumor cells themselves (as noted above
and in Supplementary Figs. 10E and 11A for the Cds2 vMOs).
All of the treatments described above involve systemic inhibition
of PI recycling. In order to show that the effects on tumor growth
are due to targeting of the tumor-associated host endothelium rather
than the tumor cells themselves, we generated inducible EC-speciﬁc
Cds2 knockout (ECKO) mice by crossing the Cad5(PAC)-CreERT2
EC speciﬁc Cre line42 to Cds2tm1a(KOMP)Wtsi (i.e. Cds2lox/lox)
mice43. Tamoxifen was supplied to the indicated mouse groups for 5
consecutive days prior to the implantation of LLC tumors into the
ﬂanks and then suspended for the remainder of the study. LLC
tumors from the Cad5(PAC)-CreERT2;Cds2lox/lox +TMX (homozygous lox cassette, CreiECΔ, +TMX- experimental deletion group)
show decreased tumor volume and decreased ﬁnal tumor weight
compared to all seven other control groups (Fig. 3a–d). Western blot
data of EC’s isolated from LLC tumors from Cad5(PAC)-CreERT2;
Cds2lox/lox +TMX mice shows maintained, signiﬁcant suppression
of CDS2 protein at the end of the 14 day experimental time
course (Fig. 3e). Examination of tumor vessel density by CD31
immunostaining of tumor versus liver sections revealed ~60%
reduction in tumor vessel area compared to controls, with no effects
on the liver vessel density (Fig. 3f–k). Importantly, for all inhibitor,
MO and ECKO treatments, routine daily veterinary checks of mice
in all groups did not reveal any adverse consequences, including in
the ECKO group following tamoxifen treatment. Cds2-deleted
ECKO mice ate normally and did not exhibit signs of illness
throughout the course of the experiment. They also exhibited
normal social interaction, grooming, and other behaviors. Some of
the experimental groups implanted with tumors did become
moribund and exhibit some lethargy as tumors grew large near
the point of ﬁnal sacriﬁce. This was much less evident in the ECKO
tumor-implanted mice, where tumor growth was restrained
compaired to the control tumor-implanted sibling groups which
developed larger tumors prior to the point of sacriﬁce. These
ﬁndings, and similar observations from our vMO, L-690,488, and
LiCl experiments (Supplementary Figs. 11B, 12A, and 13N), suggest
that anti-PI recycling treatments, as performed in our studies, do
not result in harmful effects to the mice.
The results described above show that anti-phosphoinositide
(PI) recycling treatments effectively reduce tumor growth via
impaired tumor angiogenesis in LLC or B16-F10 allografted mice
without signiﬁcant effects on the endogenous vasculature of the
liver in the same animals. We hypothesized that the increased
sensitivity to anti-PI recycling treatments of tumor versus normal
vessels might reﬂect increased signaling and increased PI substrate
utilization in “activated” tumor-associated ECs compared to
“quiescent” ECs in endogenous tissues and organs (Fig. 4a). We
examined this in two ways: (1) by ELISA quantitation of PIP2
levels in ECs obtained from tumors and lungs collected at the
termination of 14-day experiments from tumor-allografted
animals, and (2) by measuring active ERK1/2 and AKT in ECs
from immunostained histological sections from tumors and livers
of these same mice (Fig. 4b). Tumor ECs show substantially higher
phospho-ERK1/2 and phospho-AKT levels (Fig. 4c, i (upper left
panel), n (upper left panel)), as well as higher PIP2 levels (Fig. 4d)
compared to liver or lung ECs (respectively). The increased
angiogenic signaling normally present in tumor-associated ECs,
compared to ECs in endogenous host tissues, supports the idea
that systemic administration of PI recycling inhibitors within an
appropriate therapeutic window could result in strong effects on
“activated” tumor ECs with little or no effect on normal
“quiescent” ECs.

NATURE COMMUNICATIONS | (2020)11:1204 | https://doi.org/10.1038/s41467-020-14956-z | www.nature.com/naturecommunications

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14956-z

a

b

LLC tumor allograft treatment regimen

Representative
LLC tumors

Daily IP injections
of tamoxifen for 5 days prior to
tumor injection into Cds2lox mice

Day 0

Day –5

LLC tumor cells
injected into
each flank at
day 0

Day 8

Day 4

Day 12–18

lox/lox

Cad5(PAC)-CreERT2;Cds2

Tumor cells injected
bilaterally into
mouse flanks

Take final tumor weight,
volume, and vessel density
measurements

Start daily volume
measurements once
tumors become visible

Cad5(PAC)-CreERT2) + TMX

lox/lox

Cad5(PAC)-CreERT2;Cds2

+ TMX

Vascular specific Cds2 inactivation inhibits LLC tumor allograft growth

d

100
50
x
lo

X
;C

x/

T2

lo

2

re
ER

;C

)-C

T2

x/
lo

2
ds

+

x
lo

+
x/
lo

C

ds
;C
T2
re

ER

ER

ad

C

C

ad

C

5(
ad

TM

TM

2
ds

+

x
lo
x/

C

X

lo
x/
lo

X

)

TM

T2
re
ER

)-C
C

2
ds

ad

)-C

lo

TM
pe

T2

re
ER

ty

14

)-C

13

AC

12

re

11

)-C

10

C

9

PA

8

Days post-tumor injection

5(
P

7

C

6

5(

5

ad

4

+ TMX

lox/lox

PA

0

lox/lox

C

Cad5(PAC)-CreERT2;Cds2

ild

Cad5(PAC)-CreERT2;Cds2

)+

+

+ TMX

W

500

X

X

x

0
lox/+

Cad5(PAC)-CreERT2;Cds2

2

Cds2lox/lox

1000

AC

+ TMX

C

Cds2

150

TM

lox/lox

200

+

Cad5(PAC)-CreERT2)
1500

250

ds

Cad5(PAC)-CreERT2) + TMX

PA

Relative LLC tumor volume
(% of starting control value)

Wild type + TMX

5(
P

2500

2000

Tumor final weight
300

LLC average tumor
weight (% of control)

Tumor volume

5(

c

Vascular specific Cds2 inactivation inhibits tumor induced angiogenesis
CDS2 protein is suppressed
in EC’s collected from
conditional KO mice

e

f

g

Tumor vascular density

Liver average vessel
density (% of control)

X

LLC average vessel
density (% of control)

TM
+

x

/lo

re
ER
)T
PA Cre 2;C
E
d
C
)-C RT s2 lox
/lo
re 2 +
x
ER
T
T2 MX
;C
ds
2 lox

)-C

C

50

100
Wild type
+ TMX

50

j
X
TM

X
TM
lo

x

+

+

lo

2

x/

x/
lo

2

ds

ds

;C
T2

Cad5(PAC)-CreERT2, Cad5(PAC)-CreERT2,
lox/+
lox/lox
+ TMX
+ TMX
Cds2
Cds2

ER

ER

PECAM (green)

5(
PA
C

)- C

re

re
)-C

PA
C

ad

5(
ad

;C
T2

)-C
C
PA
5(

ad
C
C

k

+

X
TM

X
T2

+
pe

re
ER

ty
ild
W

T2
re
ER

)- C
5(
PA
C

ad
C

+

TM

X
TM

X
TM
lo
x/
lo

2
ds
;C

;C
T2
ER

re
)- C

x

+

+
x/
lo

2
ds

ER
re
)-C
PA
C

+

X
TM

X

+

TM
T2

+
pe
ty
ild
W

AC
5(
P
ad
C

5(
ad
C

Cad5(PAC)-CreERT2
+ TMX

C

5(

0

0

To determine whether systemic inhibition of PI recycling
preferentially reduces pro-angiogenic signaling in tumorassociated ECs but not in quiescent endogenous ECs, we
analyzed ECs from both tumors (Fig. 4e–i, o–q) and from livers/
lungs (Fig. 4j–n, r–t) of the same Cds2 vMO (Fig. 4e–n) or L690,488 (Fig. 4o–t) treated, LLC-allografted mice using immunostaining and western blot analysis. Tumor-associated ECs
from LLC-allografted, Cds2 vMO-treated mice show markedly
reduced levels of PIP2, p-AKT, and p-ERK1/2 (Fig. 4e–g, i;
Supplementary Fig. 14G–L). Consistent with previous reports in
the literature27–29,44,45 we ﬁnd that p-AKT and p-ERK1/2 are
more strongly activated in tumor-associated blood vessels than
in the surrounding tumor tissue, although longer-exposure
images conﬁrm that p-AKT and p-ERK1/2 are indeed also
present in the surrounding tumor cells (Supplementary Fig. 14M,
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N). In contrast to the tumor EC ﬁndings, EC from lungs and
livers collected from the same LLC-allografted Cds2 vMOtreated mice that the tumors were isolated from show no
reduction in levels of PIP2, p-AKT, or p-ERK1/2 (Fig. 4j-l, n;
Supplementary Fig. 14B–E). Importantly, tumor and liver/lung
ECs from the same animals show comparable reductions in
CDS2 protein levels (Fig. 4h, m; Supplementary Fig. 14A, F, G,
L). Similar differential effects on tumor versus liver EC p-ERK1/
2 and p-AKT activation were noted in mice treated with the
IMP inhibitor L-690,488 (Fig. 4o–t).
Finally, to determine whether systemic inhibition of PI recycling
can slow the growth of pre-existing tumors, we allografted LLC
tumors into mice and allowed the tumors to grow and establish.
Mice were then administered Cds2 translation-blocking (vMO #1)
or splice-blocking (vMO #2) vMO, versus a control vMO daily
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Fig. 3 Endothelial-speciﬁc genetic deletion of Cds2 promotes tumor growth inhibition. a Schematic of Lewis Lung Carcinoma (LLC) tumor allograft
assay in endothelial-speciﬁc Cds2 knockout mice. b Representative tumor images from Vehicle Control (Cad5(PAC)-CreERT2;Cds2lox/lox); Cre, TMX
Control (Cad5(PAC)-CreERT2 +TMX); and endothelial-speciﬁc Cds2 genetic deletion mice (Cad5(PAC)-CreERT2;Cds2lox/lox +TMX). Bar = 1 cm.
c, d Quantitation of LLC average tumor volume (c) and ﬁnal tumor weight (d) at 14 days post- tumor implantation in the eight genetic conditions tested.
Data in c are normalized to the starting day 4 tumor volume of Wild type + TMX controls. e Representative western blot images of EC protein isolated
from tumors for each indicated genetic condition, probed for CDS2 and tubulin as a loading control. Blots demonstrate that CDS2 protein is still reduced
in Cad5(PAC)-CreERT2;Cds2lox/lox mice at day 14, after only a 5 day pulse of TMX treatment initiated prior to the start of the experiment. p ≤ 0.05, error
bars ± SEM. *Signiﬁcance from control (t-test). f, g Quantitation of average tumor vascular density (f) and average liver vascular density (g) of CD31/
PECAM labeled LLC tumor and liver sections from control Wild type +TMX, control Cad5(PAC)-CreERT2 +TMX, control Cad5(PAC)-CreERT2;Cds2lox/+
+TMX, and endothelial-speciﬁc Cds2 genetic deletion Cad5(PAC)-CreERT2;Cds2lox/lox +TMX mice. For all vascular density measurement experiments:
three images per tumor were acquired and vascular density measured for all groups. A minimum of two slide sections from each tumor (taken from
sections at least 10 slices apart) were analyzed. p ≤ 0.05, error bars ± SEM. Star indicates signiﬁcance from control (t-test). h–k Representative images
of CD31/PECAM labeled blood vessels in tumors from control Wild type +TMX, control Cad5(PAC)-CreERT2 +TMX, control Cad5(PAC)-CreERT2;
Cds2lox/+ +TMX, and endothelial-speciﬁc Cds2 genetic deletion Cad5(PAC)-CreERT2;Cds2lox/lox +TMX mice. Bar =100 μm. Naming key: Wild type +
TMX (no Cre, no Cds2 lox cassette; n = 18); Cad5(PAC)-CreERT2 +TMX (CreiECΔ only, +TMX; n = 13); Cad5(PAC)-CreERT2 (CreiECΔ only, no TMX
vehicle control; n = 9); Cds2lox/lox +TMX (only homozygous Cds2 lox cassette, +TMX, no Cre; n = 6); Cds2lox/lox (only homozygous Cds2 lox cassette,
no TMX vehicle control; n = 9); Cad5(PAC)-CreERT2;Cds2lox/+ +TMX (CreiECΔ, Cds2 heterozygous lox cassette, +TMX; n = 16); Cad5(PAC)-CreERT2;
Cds2lox/lox +TMX (homozygous lox cassette, CreiECΔ, +TMX− experimental deletion group; n = 12); Cad5(PAC)-CreERT2;Cds2lox/lox (homozygous lox
cassette, CreiECΔ, no TMX vehicle control; n = 7). Box plots are graphed showing the median versus the ﬁrst and third quartiles of the data (the middle,
top, and bottom lines of the box, respectively). The whiskers demonstrate the spread of data within 1.5x above and below the interquartile range. All
data points are shown as individual dots, with outliers shown above or below the whiskers.

through retro-orbital injections (Fig. 5a). LLC-allografted mice
treated with either of the two Cds2 vMOs show decreased tumor
volume and decreased ﬁnal tumor weight compared to control
vMO-injected mice (Fig. 5b–d). Quantitation of tumor vessel
density in CD31 immunostained sections revealed an ~70–80%
reduction in vessel area in LLC tumor allografts from either of the
Cds2 vMO-treated animals compared to controls (Fig. 5e–h).
To determine whether systemic inhibition of PI recycling still
preferentially reduces signaling in tumor-associated ECs as
compared to quiescent endogenous ECs in this model of preexisiting tumors, we analyzed ECs from lungs (Supplementary
Fig. 15A–E) or tumors (Supplementary Fig. 15F–J) of the same
Cds2 vMO treated, LLC-allografted mice via Western blot analysis.
ECs collected from the tumors have reduced PIP2, p-AKT, pERK1/2, and CDS2 protein levels following Cds2 vMO treatment
as compared to control treatments (Supplementary Fig. 15F–J),
while EC from lungs of the same Cds2 vMO-treated mice show
minimal or no reduction in PIP2, p-AKT, or p-ERK1/2 levels
(Supplementary Fig. 15A–E), despite comparable reduction in
CDS2 protein levels.
Taken together, these data show that systemic inhibition of PI
recycling causes angiogenic defects in the tumor-associated
vasculature, but has little effect on the pre-existing stable lung
or liver vasculature of the same animals.
Discussion
In this study we show that reduced capacity of ECs to recycle PI
substrates results in speciﬁc defects in angiogenesis and VEGFmediated signal transduction that correlate with reduced levels of
PIP2 in highly active EC populations, such as the tumor vasculature. Zebraﬁsh lacking CDP-diacyglycerol synthase 2 (Cds2), one
of two enzymes required for re-synthesis of CDP-diacylglycerol
(CDP-DAG) from diacylglycerol (DAG), show speciﬁc defects in
sprouting and growth of angiogenic vessels, while appearing
otherwise normal through early larval stages of development16.
Zebraﬁsh with maternal depletion of the Impase, the enzyme
required for the re-sysnthesis of myo-inositol, show this same
defect. These results suggest that the highly active angiogenic ECs
present in developing vascular networks may be utilizing phosphoinositide signaling and consuming PI substrates to a greater
extent than most other cell types.
8

We show that ECs are not only sensitive to reduced capacity to
re-synthesize phosphoinositides, but that this sensitivity is exacerbated by increasing VEGFA stimulation (Fig. 1, Supplementary
Fig. 1). VEGFA has a well-documented role as a key pro-angiogenic
ligand- increased VEGFA stimulation typically leads to increased
angiogenic sprouting and growth of vessels. Our results show,
however, that VEGFA stimulation of ECs with compromised
capacity to recycle phosphoinositides has the seemingly paradoxical
opposite effect, resulting in less VEGFA-dependent signaling and
less vessel growth. This suggests that targeting phosphoinositide
recycling might prove to be a useful approach for anti-angiogenic
cancer therapy, as tumors increasing VEGFA production in
response to oxygen or nutrient deprivation resulting from vascular
insufﬁciency caused by inhibition of tumor endothelial PI recycling
might actually increase, rather than decrease, the effectiveness of
these types of inhibitors (Fig. 6). We demonstrate here that inhibiting phosphoinositide recycling in vivo does result in reduced
tumor growth, reduced tumor angiogenesis, reduced angiogenic
signaling, and reduced PIP2 levels in the tumor-associated vasculature in multiple murine tumor allograft models without apparent
effects on the normal, quiescent vasculature of the same animals
(Figs. 2–5 and Supplementary Figs. 10–15).
We would note again that CDS2 and IMP knockdown and the
other treatments we employ in this study only result in a partial
loss of phosphoinositide recycling capacity. Our data suggests
that in normal “resting” tissues, or even in moderately angiogenically active vessels, the residual capacity to recycle PIs by
secondary CDS or IMP enzymes is adequate to regenerate sufﬁcient PI substrates to maintain baseline intracellular signaling
(Fig. 4 and Supplementary Figs. 14, 15). On the other hand, under
conditions of high angiogenic stimulation, such as in B16-F10 or
LLC tumor-associated vessels or in highly angiogenically active
developing vessels in the zebraﬁsh, vascular defects appear
(Figs. 1 and 4, and Supplementary Figs. 1, 3, 5). Although we did
not observe any obvious negative effects of our anti-PI recycling
treatments in mice, it remains to be seen whether longer term
anti-PI recycling treatments might eventually lead to some effects
on angiogenically active normal tissues. However, some hints to
the long-term sustainability and effectiveness of anti-PI recycling
therapies may possibly be gleaned from the historically welltolerated and continued use of LiCl for management of bipolar
disorder and cognitive impairment in human patients30,46–48.
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Fig. 4 Systemic anti-PIP2 recycling therapies suppress VEGFR2 downstream signaling in LLC tumor models. a Model for signaling in activated versus
quiescent endothelium. b Diagram illustrating tissues isolated from mice and their use. c Quantiﬁcation of vascular phospho-ERK1/2 (black bars) and
phospho-AKT (gray bars) levels in immunostained liver or tumor tissue from LLC-allografted control animals (n = 8). d ELISA measurement of PIP2 levels
in lung or tumor endothelial cells from LLC-allografted control animals. Data is the average of three experimental replicates. e–n Cds2 vMO-treated, LLCallografted mice. Quantiﬁcation of PIP2 levels by ELISA in tumor (e) or lung (j) endothelial cells isolated from the same LLC-allografted animals. Data per
treatment condition is graphed as the average of three experimental replicates. The ELISA measurements are normalized to whole cell tubulin lysates
collected at the start of the lipid isolation procedure. Quantiﬁcation of vascular phospho-ERK1/2 (f, k), phospho-AKT (g, l) and CDS2 (h, m) levels from
immunostained sections of tumor (f–h) or liver (k–m) tissue collected from the same LLC-allografted animals. For all immunostaining quantitation
experiments: three images per individual tumor or liver were acquired and signal intensity measured for all groups. A minimum of two slide sections from
each tumor or liver (taken from sections at least 10 slices apart) were utilized for independent analysis. Tumors, n = 10; Livers, n = 5. i, n Representative
images of tumor (i) or liver (n) sections from control or Cds2 vMO-treated mice, double immunostained with phospho-ERK1/2 antibody (green images)
and PECAM antibody (red images). o–t L-690,488-treated, LLC-allografted mice. Quantiﬁcation of vascular phospho-ERK1/2 (o, r) and phospho-AKT
(p, s) levels from immunostained sections of tumor (o, p) or liver (r, s) tissue collected from the same LLC-allografted animals. q, t Representative images
of tumor (q) or liver (t) sections from control (DMSO) or L-690,488-treated mice, double-immunostained with phospho-ERK1/2 antibody (green images)
and PECAM antibody (red images). Control tumors, n = 8; L-690,488 tumors, n = 16; control livers, n = 4; L-690,488 livers, n = 8 p ≤ 0.05, error bars ±
SEM. Star indicates signiﬁcance from control (t-test). Bars = 200 μm. Box plots are graphed showing the median versus the ﬁrst and third quartiles of the
data (the middle, top, and bottom lines of the box, respectively). The whiskers demonstrate the spread of data within 1.5x above and below the interquartile
range. All data points are shown as individual dots, with outliers shown above or below the whiskers.
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Fig. 5 Systemic Cds2 suppression inhibits growth of established tumors. a Schematic of established tumor allograft assay. Lewis Lung Carcinoma (LLC)
tumor cells were injected into each ﬂank of adult B6/C57 mice at day 0 and tumors allowed to develop for 12–15 days. Daily intravenous injections of
control vivoMorpholino (vMO) or vMO targeting one of two independent sites in the Cds2 gene (vMO #1 and vMO #2) were started at day 4 after tumor
implantation. Volume measurements were taken daily starting at day 4, when tumors became visible and vMO treatment started, with ﬁnal tumor volumes
and weights taken at the termination of the experiment. b Quantitation of daily average tumor volume (in mm3) of LLC tumors, normalized to the average
starting size of each tumor condition at day 4 (the injection start date). c Quantitation of average tumor weight (in mg) of LLC tumors at 14 days posttumor implantation. Control vMO (n = 9); Cds2 vMO #1 (n = 8); Cds2 vMO #2 (n = 6). d Images of tumors collected from control vMO or Cds2 vMOtreated animals at 14 days post-tumor implantation. Bar = 1 cm. e Quantitation of LLC tumor vessel density in control vMO- versus Cds2 vMO-treated
mice. f–h Representative images of CD31/PECAM labeled (green) LLC tumor sections from control vMO (f) and Cds2 vMO (g, h) treated mice. White
arrowheads indicate sites of CD31/PECAM positive blood vessel labeling. For all vascular density measurement experiments, three images per tumor were
acquired (see tumor numbers above) and vascular density measured for all groups. A minimum of two slide sections from each tumor (taken from sections
at least 10 slices apart) were utilized for independent analysis. Bar = 100 μm. Box plots are graphed showing the median versus the ﬁrst and third quartiles
of the data (the middle, top, and bottom lines of the box, respectively). The whiskers demonstrate the spread of data within 1.5x above and below the
interquartile range. All data points are shown as individual dots, with outliers shown above or below the whiskers.

In our work, we demonstrate anti-angiogenic, anti-tumor
effects of LiCl and L-690,488, two chemical inhibitors that target
the IMPase enzyme to prevent PI/PIP2 regeneration (Figs. 2 and 4,
and Supplementary Fig. 13). Myo-inositol, the downstream product of IMPase that both chemicals block the production of30, is
able to signiﬁcantly rescue the inhibitory effects elicited by these
drugs (Figs. 2 and 4, and Supplementary Fig. 13). This rescue
suggests that many of the anti-angiogenic, anti-tumorigenic effects
we note in our inhibitor treatments are directly related to PI
recycling and not off-target effects, though the exact mechanism
requires further investigation. Since lithium is already used in the
management of bipolar disorder30, it would be of interest to
determine whether patients treated with lithium display a reduced
risk of cancer or cancer related morbidity compared to the general
population. At present, the epidemiologic data related to cancer
10

incidence are inconclusive, likely due in part to small sample sizes
in the studies carried out and the complexity of the populations
being evaluated, with some studies reporting reduced rates of
cancer mortality and morbidity49,50 and others not reporting such
an association51–53. Additional, carefully designed studies using
large patient populations will be needed to better examine whether
there is a demonstrable link between cancer risk and lithium use.
However, as noted above, the historic use of lithium in patient
populations suggests that at therapeutically appropriate doses,
treatment with IMPase inhibitors can be well-tolerated over time.
In conclusion, our ﬁndings highlight the role that phosphoinositide recycling plays in tumor angiogenesis, and suggest that
targeted inhibition of PI recycling may provide a useful antiangiogenic modality for the treatment of cancer (Fig. 6). The
seemingly paradoxical sensitivity of ECs subjected to anti-PI
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y54genotypeR- 5′-ATGAGGGTGTGGATGATGATGATA-3′. PCR products
were then digested with MseI cutting the PCR products carrying mutant cds2
into 193 and 124 bp fragments versus wild-type cds2 products that do not cut
generating a 317 bp PCR product. All ﬁsh were housed as pairs in genotyping
tanks (R&D Aquatics).
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Fig. 6 Proposed model for inhibition of tumor growth with anti-VEGF
versus anti-PI recycling therapies. a Currently available anti-angiogenic
therapies targeting VEGF lead to an initial decrease in tumor growth and
angiogenesis. However, production of high levels of pro-angiogenic ligands
by tumors results in a relapse in vascular impairment and return of tumor
growth. b Our results indicate that targeting PI recycling leads to reduced
tumor vasculature and tumor growth, and further suggest that the effects
on tumor angiogenesis and tumor growth may be strengthened, not
overcome, as tumor production of VEGFA and/or other cytokines
increases.

recycling treatments suggests that high levels of tumor-secreted,
pro-angiogenic cytokines may facilitate the effectiveness of antiPI recycling therapies rather than overcome them (Fig. 6). Our
data also raises the possibility that anti-PI recycling therapy might
not only inhibit tumor angiogenesis, but be even more effective
against aggressive tumors overexpressing high levels of VEGFA
and other pro-angiogenic cytokines that have traditionally been
the most refractory to treatment25,26. Additional studies will be
needed to determine whether anti-PI recycling does indeed provide a useful therapeutic modality for treatment of these aggressive cancers.
Methods
Zebraﬁsh methods. Zebraﬁsh (Danio rerio) embryos were raised and maintained
as described54,55. The Tg(ﬂi1a:EGFP)y1 transgenic zebraﬁsh line was previously
described2. The cds2y25 and cds2y54 mutants were identiﬁed in an F3 genetic screen
in the Tg(ﬂi1a:EGFP)y1 background as described previously16. The impa2 y602
mutant in the Tg(ﬂi1a:eGFP)y1 background was newly generated for this manuscript. Embryos imaged at developmental stages later than 36 hpf were treated with
1-phenyl-2-thiourea to inhibit pigment formation55. Zebraﬁsh husbandry and
research protocols were reviewed and approved by the NICHD Animal Care and
Use Committee.
Genotyping assays for cds2y25 and cds2y54 mutants. cds2y25: Zebraﬁsh carrying
the cds2y25 mutation were genotyped using KBiosciences Competitive AlleleSpeciﬁc PCR genotyping system (KASP) assays. Assays were performed on zebraﬁsh adult or embryonic genomic DNA extracts. Primer mixes with two 5′ ﬂuorlabeled oligos that bind to allele-speciﬁc primers are provided with a common 3′
oligo, as per the manufactures design. y25FAM, 5′-CAGCGGGAGGAGCC
TCTTC-3′ and y25HEX- 5′-GCAGCGGGAGGAGCCTCTTT-3′; y25common, 5′AAATGA AGCGATGGTATTTGCTGAGGATT-3′. Details on assay and primer
design can be obtained from KBioscience. The following PCR program was
designed to determine wild-type versus mutant PCR fragments: (1) 94 °C, 15 min;
(2) 94 °C, 20 s; (3) 61 °C 1 min; (4) GOTO step 2 9x and decrease temperature in
step 3 by 0.6 °C each cycle; (5) 94 °C, 10 s; (6) 55 °C, 1 min; (7) GOTO step 5 35x;
(8) 25 °C, 5 min; Plate Read and End. As primers are labeled with ﬂuorophores,
homozygous products express only one ﬂuorescent signal while heterozygous
products will result in a mixed ﬂuorescent signal.
cds2y54: PCR was performed on zebraﬁsh adult or embryonic genomic
DNA extracts using REDTaq ReadyMix PCR Reaction Mix and the following
primers: y54genotypeF- 5′-AACAGCTTGATGTAGCACAGCAGAGTA-3′;

Zebraﬁsh expression constructs, CRISPR and morpholinos. CMV:vegfaa- pCS2
(+)-zvegf165 was a gift from Dr. Ruowen Ge (National University of Singapore).
CMV promoter-driven zebraﬁsh vegf165 DNA for injection was generated as previously described. DNA was injected at a ﬁnal concentration of 75 ng/μL. Zebraﬁsh
pCR-plcg1 was MluI digested and pCSDest-pik3cd or pik3c2b was ClaI digested for
1 hour prior to DNA injection at the single cell stage at 75–100 ng/μL.
Morpholino antisense oligonucleotides (Genetools) used in this study include:
cds2 ATG MO: 5′-TCGCTGTCGTAATTCTGTCATGGTG-3′ that targets −4
to 21 of the 5′ untranslated region and coding region of cds2 (1.8 ng was used as a
maximal dose);
vegfaa: 5′-CTCGTCTTATTTCCGTGACTGTTTT-3′ (6 ng was used as a
maximal dose). The cds2 and vegfaa morpholinos used have both been previously
validated16,56. Morpholino injections were performed on zebraﬁsh embryos in the
1– cell stage as previously described in ref. 2. Maximal doses were determined
by titration of morpholinos to levels that yielded maximal vascular-speciﬁc
phenotypes with little to no nonspeciﬁc toxic effects.
PI4K inhibitor (PIK-93, #B-0306, Echelon Biosciences) was resuspended in
DMSO and used on the zebraﬁsh at 20-40 uM.
The impa2 y602 mutant allele was generated using the CRISPR/Cas9 system. The
following guide RNAs were transcribed in vitro using the MEGAscript T7 Kit
(Invitrogen), and injected at a dose of 150 pg/nl per embryo:
TAATACGACTCACTATAGGGCGTCAGGTTTATTGGTGGTTTTAGAGC
TAGAA.
pT3TS-nCas9 (Addgene) was transcribed using MEGAscript T7 Kit
(Invitrogen), and injected at a dose of 300 pg/nl per embryo. Embryos were injected
at the single cell stage, screened for cutting efﬁciency and grown on system. F1
generations were analyzed for mutations, and pairs crossed for analysis in the F2
and beyond generations.
ABI 3130xl Fragment Analyzer Protocol for Genotyping impa2 y602 mutants.
PCR protocol with AmpliTaq Gold DNA Polymerase 1×(10 μl) Rxn: 1 μl 10x
PCR Gold Buffer; 0.5μl MgCl2 25 mM; 1 μl 0.5 mM ABI Fwd primer; 1 μl 1 mM
ABI Rev primer; 0.2 μl 10 mM FAM-M13 primer; 0.1 μl dNTP Master Mix; 0.1 μl
TaqGold polymerase; 1 μl of 1:10 diluted crude gDNA; 5.1ul H2O.
TaqGold PCR Program: 95 °C 10 min; 95 °C 30 s; 58 °C 30 s; 72 °C 30 s (1 min/kb);
GoTo Step 2 x34; 72 °C 10 min; 15 °C Hold; Run on ABI immediately or store at 4 °C
in the dark for 24 h max.
ABI 3130xl Pate set-up: HiDi Formamide/ROX master mix- 0.2 μl ROX300HD;
9.8 μl HiDi Formamide; add 10 μl of master mix to each ABI plate sample well; add
2 μl of ﬂuorescent PCR product; cap wells and denature at 95 °C for 5 min; uncap
all wells and replace with ABI plate septa to run on the 3130xl. Follow
manufacturer directions to utilize the ABI 3130xl.
Gene Speciﬁc primers for genotyping:
impa2:
FW-M13: TGTAAAACGACGGCCAGTCTTACTGTGACATGTTAATGTGA
TG
RV-PIG Tail: GTGTCTTGCACAAAGTTACAGGTGCCGTCGATG
FAM-M13: 5′-/56-FAM/ TGTAAAACGACGGCCAGT-3′.
siRNA transfection and validation. Invitrogen single SilencerSelect or Stealth
siRNAs for CDS2 versus a siRNA negative control (control) were purchased and
resuspended in H2O at a concentration of 10 μM. siPORT Amine (ThermoFisher
#AM4503) was used as a transfection agent following manufacturer recommendation (siRNA target sequences in Supplemental Table 1). A double transfection
protocol, with a day of “rest” between treatments, was used as previously
described6,57 with a ﬁnal concentration of 50 nM siRNA per transfection condition.
Validation of CDS2 siRNA suppression was previously reported16 but reconﬁrmed
here by western blot. The siRNA sequences utilized are as follows:
CDS2 #1 (Stealth): GAGUACAACAAUGACACCAACAGCU
CDS2 #2 (Silencer Select): GUUUUAUCAGAGGCCCUAAUU
PIP5K1C (Silencer Select- Validated): GCGUCGUGGUCAUGAACAAtt
PI4K2A (Silencer Select- Validated): CCAAAGAUAUCGGACCCUAtt
PI4K2B (Silencer Select- Validated): GAUUGACCGUGCAAAAUCAtt.
Endothelial cell culture and assays. HUVECs (Lonza) were cultured in bovine
hypothalamus extract, 0.01% Heparin and 20% FBS in M199 base media (Gibco)
on 1 mg/mL gelatin-coated tissue culture ﬂasks. HUVECs were used from
passages 3–6.
3-dimensional (3D) in vitro angiogenesis assays were done in 2.5 mg/mL
collagen type I (BD Bioscience, Acid Extracted) gels, prepared including SCF (R&D
Systems, #255-SC/CF), SDF1α (R&D Systems, #350-NS/CF) and IL-3 (R&D
Systems, #203-IL/CF in the gel at 200 ng/mL and VEGFA (R&D Systems, #293-VE/
CF) at the indicated doses described in the manuscript, essentially as described6,57.
HUVECs were seeded on the gel surface at a density of 40,000 cells/well.
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Culture media included FGF (200 ng/mL; R&D Systems, #233-FB-025/CF), IGF-II
(200 ng/mL; R&D Systems, #292-G2-250), and ascorbic acid (Sigma). Assays were
ﬁxed in 3% glutaraldehyde at the indicated time points and processed for future
analysis. Cells were stained with 1% toluidine blue in 30% methanol to increase
visualization before imaging. Data analysis was done by imaging the endothelial
cell invasive front at 3 depths below the monolayer of cells (~50 μM apart in
depth). Images were obtained and the number of endothelial cells present at each
depth counted; the counts at the 3 depths were added together to give a total
number of invading cells per well. A minimum of ﬁve replicate wells was averaged
to give a mean ± SD within a single experiment. At least 2 experimental replicates
were performed. Data is represented as a percentage of the 10 ng/ml VEGFA
Control siRNA condition (Fig. 1j- % Average number of invading cells) or as a
percentage of invasion inhibition at each indicated VEGFA dose (Fig. 1hcalculated by taking % Invading number of CDS2 KD cells/% Invading number of
Paired Control cells = % Invasion Inhibition).
For signaling activation assays, endothelial cells were seeded as a conﬂuent
monolayer for 24 h in full growth media. The morning of the assay, cells were
serum starved in basal 1x M199 media for 4 h. The indicated growth factors/ligands
were then supplied at a dose of 40 ng/ml in the basal media for 10 min. Lysates
were collected and analyzed following the methods outlined below.

secondary antibody in 5% Sheep Serum, 1% Roche Blocking Buffer in PBST; (7)
wash with PBST and imaging analysis. For mouse tumor and tissue slide sections:
the same essential staining protocol was utilized following (1) incubation of the
slides at 50 °C to melt the parafﬁn wax, (2) 3x, 10 min wash in Histoclear (xylene
alternative), (3) 2x, 5 min wash 100% EtOH, (4) 5 min was, 90% EtOH, (5) 5 min
wash 70% EtOH, (6) continue to above staining procedure. All tissues were
mounted and sectioned using the services of Hisoserv, Inc, Germantown,
Maryland. All slides stained for p-AKT and p-ERK1/2 were co-stained with
PECAM/CD31 antibody to conﬁrm vascular expression for quantiﬁcation
purposes.
Quantiﬁcation of immunostaining intensity was performed by ImageJ analysis
software. Images were acquired using a Leica SP5 II confocal microscope. All
images were acquired at the same intensity, step size and image resolution for
analysis. Data is reported as the percent average intensity per region of interest size.
For all vascular density measurement and pERK1/2/pAKT ﬂuorescent quantitation
experiments three images per tumor were acquired (see tumor numbers in the
ﬁgure legends) and average measurements taken for all groups. A minimum of two
slide sections from each tumor (taken from sections at least 10 slices apart) were
utilized for analysis, data ± s.e.m. Vascular expression of p-AKT and p-ERK1/2 was
in every case conﬁrmed by co-staining with PECAM/CD31 antibody.

PI isoforms quantiﬁcation. siRNA-treated HUVECs were plated on collagen type
I-coated plastic wells, allowed to attach overnight and then treated with the indicated doses of rhVEGFA for predetermined times prior to PI(4)P, PI(4,5)P and
PIP3 quantiﬁcation. Quantiﬁcation was done using a competitive ELISA Kits
purchased from Echelon Biosciences (Echelon Biosciences,#K-4000E, #K-4500,
#K-2500 s) or utilizing a direct ELISA protocol for measuring PIP2 levels as previously modiﬁed and described58. Lipids was extracted following Echelon Biosciences manufacturer recommendations. Absorbance was read using a plate reader
at 450 nm. No detergent was used for washes to maintain the PIP2 lipid integrity.
Samples were assessed in triplicate, normalized to cell number as assessed by
counting four individual high powered ﬁelds (trypsin treatment of the cells can
alter lipid levels and is not advised if it can be avoided), and results given as mean
relative PIP2 levels as compared to control untreated cells, error bars ± SD for a
single experiment or error bars ± SEM when averaging multiple experiments. At
least 2–3 experimental replicates were performed.
For measurements of PIP2 levels in lung ECs and tumor-associated ECs,
competitive ELISAs protocols were done as described above. Results were
normalized to input protein levels based on Western blot tubulin expression.

Tumor allografts. All animal studies were carried out according to NIH-approved
protocols, in compliance with the Guide for the Care and use of Laboratory
Animals. B16-F10 or LLC tumor cells were maintained in 10% FBS/DMEM growth
media and obtained from the JS Gutkind lab. Prior to tumor injection into B6/C57
mice, the mice were shaved to remove hair at the site of tumor growth and facilitate
tumor identiﬁcation and volume measurements. On the day of injection, the tumor
cells were trypsinized and resuspended in PBS. In all, 200 μl of PBS/cell suspension
containing 106 cells was injected into each ﬂank. For LiCl studies, normal saline
(control), LiCl (400 mg/kg), myoinositol (400 mg/kg), or LiCl+myoinositol in
200 μL normal saline were injected daily IP. For vMO (Gene Tools) studies, control
vMO (sequence: CCCTGTCCCCTACTTCGCTCATGCT), Cds2 vMO #1
(CCTCTGCCG TAGTTCGGTCATGCT), Cds2 vMO #2 (GGCTTGTCAACGA
TACTTACAATCA) were injected through the tail vein or retro-orbitally at a dose
of 40 μl of 2000 nmol stock per mouse per day. vMO were stored at room temperature and heated at 65 °C for 15 min prior to use. To verify suppression of the
CDS2 gene in vMO-treated mice, endothelial cells were isolated from the lungs at
the termination of the studies (see below), and lysed for protein analysis to verify
protein suppression. L-690,488 chemical inhibitor was purchased from Tocris
(#0682), resuspended in DMSO at 100 mM and supplied via retro-orbital injection
at a daily dose of 80uM per animal daily. For endothelial-speciﬁc genetic suppression of Cds2, tamoxifen was injected IP daily at a dose of 1 mg/mouse in corn
oil for 5 days prior to allograft of the tumors. The Cds2 mouse strain used for this
research project was created from ES cell clone EPD0033_1_C08 obtained from
KOMP Repository (www.komp.org) and generated by the Wellcome Trust Sanger
Institute, and genotyped following their explicit instructions43. The Cad5(PAC)CreERT2 were used with permission from Dr. Ralf Adams, and genotyped following their experimental protocols42. Endothelial cells were isolated from both
lungs and tumors at the end of the 14 day experiment to conﬁrm Cds2 protein
suppression. Eight groups were generated:
Wild type + TMX (no Cre, no ﬂoxed Cds2, tamoxifen added CONTROL)
Cad5(PAC)-CreERT2 +TMX (cre driver alone, tamoxifen added CONTROL)
Cad5(PAC)-CreERT2 (cre driver alone, no tamoxifen CONTROL)
Cds2lox/lox +TMX (homozygous ﬂoxed Cds2, no cre, tamoxifen added
CONTROL)
Cds2lox/lox (homozygous ﬂoxed Cds2, no cre, no tamoxifen CONTROL)
Cad5(PAC)-CreERT2;Cds2lox/+ +TMX (heterozygous EC-speciﬁc knockout)
Cad5(PAC)-CreERT2;Cds2lox/lox +TMX (homozygous EC-speciﬁc knockout)
Cad5(PAC)-CreERT2;Cds2lox/lox (cre driver, homozygous ﬂoxed Cds2, no
tamoxifen CONTROL).
For all experiments, calipers were used to measure the approximate tumor
volume daily, with ﬁnal weight measurements (mg) made at the termination of the
experiment. Tumors were allowed to grow until control tumors reached a volume
of ~500–1000 mm3, day 18 was reached, or signiﬁcant impairment to the mouse
motility from tumor burden was noted.

Liposome injections in Zebraﬁsh and mice. Puriﬁed PI(4,5)P2 liposomes
(Echelon Biosciences, #P-9045; to note- the SN2 position is 6-carbons long; the
SN1 position, where the BODIPY is attached, is 6-carbons long and joined with an
amide linker) were incubated in equal molar concentration (40 μM) with lipid
carrier constructs (Histone H1 Carrier #2, Echelon Biosciences) for 10 min at room
temperature prior to intra-vascular injection into either the zebraﬁsh or mice (via
retro-orbital injection). For zebraﬁsh studies, a single 15 nl “bolus” injection of
BODIPY labeled PIP2 was delivered over the course of 2–3 min into the sinus
venosus at 48 hpf. Only ﬁsh showing substantial and predominantly vascular
dispersion of the BODIPY labeled PIP2 were utilized for ISV quantiﬁcation analysis. Data analysis was done at 72 hpf. This same protocol was followed for PI (#C00M6, Echelon Biosciences), PI(4)P (#C-04M6, Echelon Biosciences), and PIP3
(#C-39M6, Echelon Biosciences) liposome injections. For mouse PI(4,5)P injection
studies, daily retro-orbital injections of BODIPY PIP2 liposomes were done
(40 μM) versus lipid carrier (Histone H1 Carrier #2, Echelon Biosciences) alone
conditions.
Immunoanalysis and immunostaining. Immunoanalysis: Zebraﬁsh trunk tissue
was collected using no. In all, 55 superﬁne forceps to remove the head and dissect
off the yolk ball. Tissue was directly lysed in 2x Laemmli Sample Buffer containing
5% β-ME and a PhosSTOP tablet (Roche), 10 ul per embryo. HUVEC culture
lysates were harvested directly into the same lysis buffer described above. Antibodies: p-ERK1/2 (#4370), T. ERK (#4695), p-AKT (#4060), T. AKT (#2920) (Cell
Signaling Technologies, all 1:1,000), Tubulin (Sigma; #T6199- 1:10,000), CDS2
(ProteinTech, #13175-1-AP-1:500), BODIPY (Invitrogen, #A5770- 1:1000) in 5%
BSA. Secondary HRP-conjugated antibodies were purchased from Santa Cruz or
Invitrogen and used at 1:2000 in 5% milk. Quantiﬁcation of relative band intensity
was performed by ImageJ image analysis software, with results shown from at least
two independent HUVEC assays, two independent zebraﬁsh clutches, or two-three
independent western blots from pooled EC samples collected from a minimum of
2-4 tumors/lungs. Data is reported as a percentage of control levels, and p-ERK1/2
and p-AKT are normalized to total tubulin levels.
Immunostaining: Zebraﬁsh and 3D collagen assays utilized for immunostaining
analysis were ﬁxed in 4% or 2% PFA, respectively, at 4 °C overnight. Both were
immunostained following the same basic protocol: (1) 30 min RT incubation in
Tris-Glycine; (2) 1 h RT incubation for permeabilization with 0.01% TritonX-100;
(3) 2 h RT incubation in blocking solution (5% Sheep Serum, 1% Roche Blocking
Buffer in PBST); (4) 1 h at RT or overnight 4 °C incubation with 1:1000 primary
antibody; (5) wash with PBST; (6) 2–3 h RT incubation with 1:2000 AlexaFlour
12

Measurement of tumor vascularization. B16-F10 or LLC tumors or livers from
the treatment mice were collected for analysis and parafﬁn embedded for H&E and
immunoﬂuorescent staining or preserved in OCT medium for cryo-sections. At
minimum, four livers or eight tumors of each type were embedded and serially
sectioned for vessel density analysis. Immunoﬂuorescent labeling of CD31/PECAM
(BD Biosciences #550274, 1:10) and active Caspase3 (Sigma, #C4748- 1:1000) was
done and slides counterstained with HOECHST (Molecular Probes #33342,
1:2000). Images were taken using a Leica Inverted TCS-SP5 II confocal microscope
and 20x objective. Three images were taken randomly from within the liver or the
tumor body and the average vessel area measured per high powered imaging ﬁeld.
Average vessel area was measured using ImageJ, measuring the average CD31/
PECAM+ area per high power image ﬁeld. The data are reported as a mean, error
bars ± SEM.
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Quantiﬁcation of tumor cell proliferation. For tumor cell proliferation in the
presence of LiCl: B16-F10 or LLC tumor cells were plated in 24-well plates in 500 μl
of 10% FBS/DMEM. Cells were allowed to attach and LiCl or vMO added. Estimated concentrations of LiCl were determined proportionally based off of doses
provided in vivo to the mice (whole mouse dose/approximate tissue volume = x
concentration). In all, 10 μM (estimated equivalent concentration to mouse dose)
and 20 μM (estimated double concentration to mouse dose) concentrations of LiCl
were added to the growth media daily and proliferation assessed over a multi-day
time course. Culture media was changed completely every 3 days for the duration
of the time course. For tumor cell proliferation in the presence of vMO: Concentrations for the vMOs were determined based off of the estimated mouse blood
volume (~2 ml) and proportioned to the volume of tissue culture media present in
the assay. A daily dose of 4 μl of the 2000 nmol stock per well was added to 24-well
plates containing 500 μl of 10% FBS/DMEM. Media was changed completely every
3 days. For both assays, cells were ﬁxed using 2% PFA and stained with HOECHST
dye. Five distinct images per well were assessed and the number of nuclei per well
counted. The data are reported as the averages between images ± SD.

6.

7.
8.
9.

10.
11.
12.

13.
Isolation of mouse lung and tumor-associated endothelial cells. Isolation of
mouse lung or tumor microvascular endothelial cells was performed essentially
according to a previously described protocol59. Modiﬁcations are brieﬂy described,
lungs were removed from the mice, washed in 10% FBS/DMEM, minced into
1–2 mm squares and digested with Collagenase Type I (2 mg/ml, Gibco) at 37 °C
for 2 h with occasional agitation. The cellular digest was ﬁltered through a 70 μm
cell strainer, centrifuged at 1.2 g and the cells immediately incubated with Dynabead sheep anti-rat IgG (Invitrogen) coated with a rat anti-mouse ICAM-2 mAb
(3C4, 22.5 μL of antibody per 150 ul of beads) at room temperature for 10 min. The
bead-bound cells were recovered with a magnet, washed four times, and the cells
immediately collected for protein lysates and PIP2 ELISA protocols. All isolation
steps were done in the presence of phosphatase inhibitors.
Statistics. Statistical analysis of data was done using Microsoft Excel or Plotly.
Statistical signiﬁcance was set at a minimum of p ≤ 0.05, and is indicated in
individual ﬁgure legends. Student t-tests, two tailed, were used when analyzing two
groups within a single experiment. Box plots are graphed showing the median
versus the ﬁrst and third quartiles of the data (the middle, top, and bottom lines of
the box, respectively) using Plotly. The whiskers demonstrate the spread of data
within 1.5x above and below the interquartile range. All data points are shown as
individual dots, with outliers shown above or below the whiskers.
Study approval. Zebraﬁsh and mouse husbandry and research protocols were
reviewed and approved by the NICHD and NIDCR Animal Care and Use Committee at the National Institutes of Health. All animal studies were carried out
according to NIH-approved protocols, in compliance with ethical regulations for
animal testing and research outlined in the Guide for the Care and use of
Laboratory Animals.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.

Data availability
The data sets generated and/or analyzed during the current study are available from the
corresponding author B.M.W. upon reasonable request. The source data underlying main
and supplementary ﬁgures are provided as a Source Data ﬁle.
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